Flag of the European Union EU Clinical Trials Register Help

Clinical trials for VEGF

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    645 result(s) found for: VEGF. Displaying page 1 of 33.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-002124-17 Sponsor Protocol Number: IMO-AFLI-2013-01 Start Date*: 2013-10-04
    Sponsor Name:Fundació de Recerca de L?Institut de Microcirurgia Ocular
    Full Title: Phase IV study to evaluate genetic variants of VEGF pathway as biomarkers of VEGF Trap-Eye treatment efficacy in subjects with neovascular age-related macular degeneration (wAMD).
    Medical condition: Wet age-related macular degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-001208-12 Sponsor Protocol Number: 44122 Start Date*: 2013-08-30
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Switching to aflibercept in patients with neovascular AMD not responding to anti-VEGF treatment.
    Medical condition: Neovascular Age-related macular degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2005-005026-31 Sponsor Protocol Number: EFC6125 [AVE0005A/3001] Start Date*: 2006-04-24
    Sponsor Name:Sanofi-Synthelabo Recherche, a subsidiary of sanofi-aventis group
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study of the Effect of Intravenous AVE0005 (VEGF Trap) Administered Every 2 Weeks in Advanced Ovarian Cancer Patients with ...
    Medical condition: pacientes con cáncer de ovario avanzado con ascitis maligna sintomática recurrente
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) GB (Completed) HU (Completed) AT (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-008200-40 Sponsor Protocol Number: VGFT-OD-0706 Start Date*: 2009-05-20
    Sponsor Name:Regeneron Pharmaceuticals, Inc
    Full Title: A Double-Masked, Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema (DME)
    Medical condition: Diabetic Macular Edema (DME)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002663-25 Sponsor Protocol Number: VEGFVAX Start Date*: 2014-02-06
    Sponsor Name:VU University Medical Center
    Full Title: A phase I- IIa open-label clinical trial, evaluating the therapeutic vaccine hVEGF26-104/RFASE in patients with advanced solid tumors
    Medical condition: Advanced solid tumors
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-003209-10 Sponsor Protocol Number: ML18583 Start Date*: 2005-10-18
    Sponsor Name:Tampere University Hospital
    Full Title: VEGF, VEGFR1 and VEGFR2 expression in serous epithelial ovarian carcinoma, and its association to the efficacy of bevacizumab combined with paclitaxel and carboplatin as first line treatment
    Medical condition: FIGO Stage III-IV serous epithelial ovarian carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001316-47 Sponsor Protocol Number: ML18580 Start Date*: 2005-07-05
    Sponsor Name:Turku University Central Hospital
    Full Title: Bevacizumab (Avastin™), dacarbazine and interferon α-2a (Roferon-A; IFN α-2a ) combination as a first-line therapy in patients with locally advancing or metastatic melanoma
    Medical condition: Patients with histologically confirmed metastatic melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2008-008259-41 Sponsor Protocol Number: OZR-2008-20 Start Date*: 2009-03-30
    Sponsor Name:Rotterdam Eye Hospital
    Full Title: Anti-VEGF (bevacizumab/ranibizumab) versus RPE-choroid graft in the treatment of 1) non-responders to 3 intravitreal anti-VEGF injections, or 2) patients with AMD and pigment epithelium rip, or 3) ...
    Medical condition: Age related macular degeneration and either of the following conditions: 1) not responding to 3 intravitreal anti-VEGF injections, or 2) pigment epithelium rip, or 3) massive haemorrhage.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2005-005024-14 Sponsor Protocol Number: ARD6122 Start Date*: 2006-03-28
    Sponsor Name:Sanofi-Synthélabo Recherche, a subsidiary of sanofi-aventis group
    Full Title: Estudio multicéntrico, aleatorizado, doble ciego, de grupos paralelos y en dos fases, de la eficacia y seguridad de AVE0005 (VEGF Trap) administrado por vía intravenosa cada 2 semanas en pacientes ...
    Medical condition: pacientes con cáncer de ovario avanzado resistente a platino y resistente a topotecano y/o doxorubicina liposomal.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) SE (Completed) PT (Completed) DE (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-000604-16 Sponsor Protocol Number: ARD6772 Start Date*: 2006-08-30
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A Multicenter, Open-Label, Single-Arm Study of Intravenous AVE0005 (VEGF Trap) Administered Every 2 Weeks in Advanced Ovarian Cancer Patients with Recurrent Symptomatic Malignant Ascites.
    Medical condition: Advanced ovarian cancer patients with recurrent symptomatic malignant ascites.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022364-12 Sponsor Protocol Number: BAY86-5321/91745 Start Date*: 2011-03-18
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized, double masked, active controlled, phase III study of the efficacy and safety of repeated doses of intravitreal VEGF Trap-Eye in subjects with diabetic macular edema
    Medical condition: Diabetic macular edema with central involvement
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) CZ (Completed) ES (Completed) DK (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2008-001600-23 Sponsor Protocol Number: HLS02/2008 Start Date*: 2010-01-08
    Sponsor Name:AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)
    Full Title: Prospective, randomized, single masked pilot study on the variation of choroidal blood flow analyzed through the HRA dynamic angiography in patients treated with intravitreal injection of Selecti...
    Medical condition: Choroidal neovascularization in patients with age-related macular degeneration.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002335-28 Sponsor Protocol Number: UMCGABR40641 Start Date*: 2013-01-07
    Sponsor Name:University medical centre groningen
    Full Title: Evaluation of VEGF expression with 89Zr-bevacizumab PET scan in patients with relapsing multiple myeloma; a feasibility study
    Medical condition: patients with relapsing multiple myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000848-26 Sponsor Protocol Number: BMF-AFLI-2013-01 Start Date*: 2013-07-04
    Sponsor Name:Barcelona Macula Foundation
    Full Title: Phase IV study to evaluate the efficacy of aflibercept in subjects with neovascular age-related macular degeneration (wAMD), without optimal response to repeated monthly intravitreal injections of ...
    Medical condition: Wet age-related macular degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004137-21 Sponsor Protocol Number: 2008/20 Start Date*: 2009-02-05
    Sponsor Name:CENTRE ANTOINE LACASSAGNE
    Full Title: EFFETS DU SUNITINIB DANS L'EXPRESSION DU VEGF ET DE L'INTERLEUKINE 8 : EXPLICATION DES EFFETS ANTI ANGIOGENIQUES
    Medical condition: cancer du rein métastatique
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001639-35 Sponsor Protocol Number: CRFB002DDE25 Start Date*: 2014-08-11
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, single-blinded, multicenter, phase IV study to compare systemic VEGF protein dynamics following monthly intravitreal injections of 0.5 mg ranibizumab versus 2 mg aflibercept until stu...
    Medical condition: Visual impairment due to diabetic macula edema
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10012689 Diabetic retinopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006144-55 Sponsor Protocol Number: ARD6123 [AVE0005B/2001] Start Date*: 2007-03-14
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A multicenter, open-label, single-arm, two-stage study of the efficacy and safety of AVE0005 (VEGF Trap) administered intravenously every 2 weeks in patients with platinum- and erlotinib-resistant,...
    Medical condition: patients with platinum- and erlotinib-resistant, locally advanced or metastatic non-small-cell lung adenocarcinoma.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-003986-11 Sponsor Protocol Number: 1401-MAD-004-IO Start Date*: 2016-10-22
    Sponsor Name:IVI Madrid
    Full Title: Prospective, double-blinded, randomized clinical trial to evaluate the potential benefitial effect of resveratrol for preventing the ovarian hyperstimulation syndrome.
    Medical condition: Resveratrol may prevent the incidence of ovarian hyperstimulation syndrome by reducing the expression of VEGF and estradiol, improving the haemoconcentration and ascitis Re
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001182-27 Sponsor Protocol Number: CRFB002ADE27 Start Date*: 2014-08-27
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, single-blinded, multicenter, phase IV study to compare systemic VEGF protein dynamics following monthly intravitreal injections of 0.5 mg ranibizumab versus 2 mg aflibercept until stu...
    Medical condition: Visual impairment due to neovascular AMD
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-004546-41 Sponsor Protocol Number: 220458-2004; ML18282 Start Date*: 2005-02-10
    Sponsor Name:Helsinki University Central Hospital
    Full Title: A phase II trial assessing bevacizumab in the treatment of advanced or metastatic angiosarcoma
    Medical condition: patients with advanced or metastatic angiosarcoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 19:10:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA